03:20 , Aug 17, 2018 |  BC Week In Review  |  Company News

Almirall acquires U.S. dermatology products from Allergan

Almirall S.A. (Madrid:ALM) will acquire a portfolio of five dermatology products marketed in the U.S. from Allergan plc (NYSE:AGN) for $550 million in cash. The portfolio, which generated 1H18 sales of $70 million, includes acne and...
21:12 , Jan 5, 2018 |  BC Week In Review  |  Company News

Allergan cutting jobs ahead of Restasis competition

Allergan plc (NYSE:AGN) announced details Thursday of a plan to reduce costs as it braces for potential generic competition to its blockbuster dry eye drug Restasis cyclosporine this year. The company will cut over 1,000...
23:00 , Jan 4, 2018 |  BC Extra  |  Company News

Allergan cutting jobs ahead of Restasis competition

Allergan plc (NYSE:AGN) announced details Thursday of a plan to reduce costs as it braces for potential generic competition to its blockbuster dry eye drug Restasis cyclosporine this year. The company will cut over 1,000...
07:00 , Sep 14, 2016 |  BC Extra  |  Top Story

Allergan acquiring Vitae

Allergan plc (NYSE:AGN) is acquiring Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) for $21 per share in cash, or about $639 million. The price is a 159% premium to Vitae's close of $8.10 on Tuesday, before the deal...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Clinical News

Aczone dapsone topical gel regulatory update

FDA approved Allergan’s Aczone dapsone 7.5% topical gel to treat acne vulgaris in patients ages >=12. The company already markets Aczone 5% in the U.S. and plans to launch the new product in May. Aczone...
08:00 , Nov 9, 2015 |  BioCentury  |  Strategy

Pfizer's growth spurt

Eighteen months ago, flat-to-flagging growth across Pfizer Inc.'s innovative and established products businesses suggested the pharma needed a major acquisition to shore up the units before it could move forward with a much-discussed potential breakup....
08:00 , Feb 14, 2011 |  BC Week In Review  |  Company News

Valeant Pharmaceuticals, Allergan sales and marketing update

Allergen granted Valeant's Biovail Laboratories International SRL subsidiary exclusive Canadian rights to Aczone dapsone topical gel 5% to treat acne vulgaris. Allergan will receive C$500,000 ($506,050) up front and is eligible for sales-based...
07:00 , May 18, 2009 |  BC Week In Review  |  Company News

Allergan, SkinMedica sales and marketing update

The companies will co-promote Allergan's Aczone dapsone 5% topical gel in the U.S. SkinMedica's sales force will call on pediatricians, while Allergan's will continue to target dermatologists. SkinMedica will receive a portion of sales...
07:00 , Jul 21, 2008 |  BC Week In Review  |  Company News

QLT, Allergan deal

Allergan’s Allergan Sales LLC subsidiary completed its previously announced acquisition of all worldwide assets related to QLT’s Aczone dapsone topical gel to treat acne vulgaris for $150 million in cash (see BioCentury, June...
07:00 , Jun 16, 2008 |  BC Week In Review  |  Company News

QLT, Allergan deal

Allergan’s Allergan Sales LLC subsidiary paid $150 million in cash to QLT for all worldwide assets related to Aczone dapsone topical gel to treat acne vulgaris. The topical 5% dapsone gel is approved...